Morbidity and Mortality Weekly Report: Recommendations and Reports, March 4, 1994 / Vol. 43 / No. RR-3

Details

• Alternative Title:
  1994 Revised Guidelines for the Performance of CD4+ T-cell Determinations in Persons with Human Immunodeficiency Virus (HIV) Infections
• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports
• Personal Author:
  Nicholson, Janet K. A., 1948- ; McDougal, J. Steven ; Hearn, Thomas L. ; Collins, Carlyn L. ; Velleca, Wallis M. ; Jones, Wanda K. ; Gerber, A. Russell
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.). Public Health Practice Program Office. ; National Center for Infectious Diseases (U.S.) ; National Center for Prevention Services (U.S.)
• Description:
  The Food and Drug Administration (FDA) has recommended that all donated blood be screened for antibodies to human immunodeficiency virus type 2 (HIV-2) beginning no later than June 1, 1992. This article provides CDC recommendations for the DIAGNOSIS of HIV-1 and HIV-2 infections in persons being tested in settings other than blood centers and CDC/FDA guidelines for serologic testing with combination HIV-1/HIV-2 screening enzyme immunoassays (EIAs). Epidemiologic data indicate that the prevalence of HIV-2 infections in persons in the United States is extremely low. Therefore, CDC does not recommend routine testing for HIV-2 in settings other than blood centers. However, when HIV testing is indicated, tests for antibodies to both HIV-1 and HIV-2 should be obtained if epidemiologic risk factors for HIV-2 infection are present, if clinical evidence exists for HIV disease in the absence of a positive test for antibodies to HIV-1, or if HIV-1 Western blot results exhibit the unusual indeterminate pattern of gag plus pol bands in the absence of env bands. The following procedures are recommended if testing for both HIV-1 and HIV-2 is performed by means of a combination HIV-1/HIV-2 EIA. A repeatedly reactive specimen by HIV-1/HIV-2 EIA should be tested by HIV-1 Western blot (or another licensed HIV-1 supplemental test). A positive result by HIV-1 Western blot confirms the presence of antibodies to HIV, and testing for HIV-2 is recommended only if HIV-2 risk factors are present. If the HIV-1 Western blot result is negative or indeterminate, an HIV-2 EIA should be performed. If the HIV-2 EIA is positive, an HIV-2 supplemental test should be performed.
• Subjects:
  CD4-Positive T-Lymphocytes HIV Infections Humans Immunophenotyping Quality Control Specimen Handling
• Source:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports, 1994; v. 43, no. 3
• Series:
  Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  1057-5987 (print)
• Pubmed ID:
  7908403
• Document Type:
  Journal Issue
• Place as Subject:
  United States
• Pages in Document:
  26 pdf pages
• Volume:
  43
• Issue:
  3
• Collection(s):
  Guidelines and Recommendations Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:370e0f5e729efffe995aeff7c8c996b51579c8b4c3392d5cc36a79ab830e3b0a210e81707fcdc6c832cd0e64a1a901c66e6ed29693671d2f5efae47fa5ad9a73
• Download URL:
  https://stacks.cdc.gov/view/cdc/7358/cdc_7358_DS1.pdf
• File Type:
  [PDF - 317.63 KB ]